Lactate dehydrogenase 5: identification of a druggable target to reduce oxaluria
Jacob S. Stevens and Qais Al-Awqati
Department of Medicine, Division of Nephrology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Address correspondence to: Jacob S. Stevens or Qais Al-Awqati, Department of Medicine, Division of Nephrology, Vagelos College of Physicians and Surgeons, Columbia University, 622 W. 168th Street, PH4-124, New York, New York 10032, USA. Phone: 212.305.3273; Email: jss2275@cumc.columbia.edu (JSS). Phone: 212.305.2512; Email: qa1@cumc.columbia.edu (QAA).
Find articles by Stevens, J. in: JCI | PubMed | Google Scholar
Department of Medicine, Division of Nephrology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Address correspondence to: Jacob S. Stevens or Qais Al-Awqati, Department of Medicine, Division of Nephrology, Vagelos College of Physicians and Surgeons, Columbia University, 622 W. 168th Street, PH4-124, New York, New York 10032, USA. Phone: 212.305.3273; Email: jss2275@cumc.columbia.edu (JSS). Phone: 212.305.2512; Email: qa1@cumc.columbia.edu (QAA).
Find articles by
Al-Awqati, Q.
in:
JCI
|
PubMed
|
Google Scholar
|
First published May 20, 2019 - More info
J Clin Invest. 2019;129(6):2201–2204. https://doi.org/10.1172/JCI128709.
© 2019 American Society for Clinical Investigation
Excessive excretion of oxalate in the urine results in the formation of calcium oxalate crystals and subsequent kidney stone formation. Severe forms of hyperoxaluria, including genetic forms and those that result from ethylene glycol poisoning, can result in end-stage renal disease. Therapeutic interventions are limited and often rely on dietary intervention. In this issue of the JCI, Le Dudal and colleagues demonstrate that the lactate dehydrogenase 5 inhibitor (LDH5) stiripentol reduces urinary oxalate excretion. Importantly, stiripentol treatment of a single individual with primary hyperoxaluria reduced the urinary oxalate excretion. Together, these results support further evaluation of LDH5 as a therapeutic target for hyperoxaluria.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Print subscription
- $795
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)